{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:35Z","timestamp":1793141675960,"version":"4.5.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Oral and genital ulcers are the hallmark manifestation of Beh\u00e7et\u2019s disease (BD), significantly impacting patients\u2019 quality of life. Our study focuses on comparing the effectiveness and safety of TNF inhibitors (TNFis) and apremilast in controlling oral ulcers of BD, aiming to provide evidence-based guidance for physicians in selecting appropriate treatment modalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective analysis was performed on BD patients treated between December 2016 and December 2021 with TNFis or apremilast for refractory oral ulcers. The study assessed treatment response by the absence of oral ulcers at 3 and 6\u2009months, with additional evaluations for genital ulcers and articular involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 78 patients, equally allocated between TNFis and apremilast treatments. Both groups showed significant oral ulcer reduction at 3 (P\u2009&amp;lt;\u20090.001) and 6\u2009months (P\u2009=\u20090.01), with no significant difference between the treatments. Apremilast had a notable CS-sparing effect by the 3-month follow-up, persisting through 6\u2009months. Both treatments were equally effective in reducing genital ulcers, with TNFis showing greater effectiveness in addressing articular involvement. Apremilast had a higher discontinuation rate due to gastrointestinal side effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TNFis and apremilast are both effective for treating BD refractory oral ulcers. While TNFis may offer broader benefits for other disease manifestations, apremilast is distinguished by its CS-sparing effect, especially for patients with a milder disease phenotype. Treatment selection should consider individual disease severity and clinical features to ensure a personalized and effective management strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae274","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T20:58:08Z","timestamp":1717016288000},"page":"1302-1308","source":"Crossref","is-referenced-by-count":10,"title":["Exploring relief for Beh\u00e7et\u2019s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast"],"prefix":"10.1093","volume":"64","author":[{"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Morrone","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5930","authenticated-orcid":false,"given":"Vincenzo","family":"Venerito","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Beh\u00e7et\u2019s Disease Clinic , Siena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste,","place":["Italy"]},{"name":"Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-0163","authenticated-orcid":false,"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, Carrer de Villarroe , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema Maria","family":"Lled\u00f3","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, Carrer de Villarroe , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari , Cagliari,","place":["Italy"]},{"name":"UOC Rheumatology, AOU Cagliari , Cagliari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari , Cagliari,","place":["Italy"]},{"name":"UOC Rheumatology, AOU Cagliari , Cagliari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Beh\u00e7et\u2019s Disease Clinic , Siena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Beh\u00e7et\u2019s Disease Clinic , Siena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Chiara","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Biancalana","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2995-6113","authenticated-orcid":false,"given":"Irene","family":"Mattioli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-5983","authenticated-orcid":false,"given":"Lorenza Maria","family":"Argolini","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Research Center for Pediatric and Adult Rheumatic Diseases , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Di Cianni","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana and Department of Clinical and Experimental Medicine, University of Pisa , Pisa,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9300-6169","authenticated-orcid":false,"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, Research Center for Pediatric and Adult Rheumatic Diseases , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari \u201cAldo Moro\u201d , Bari,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"2025030500183800700_keae274-B1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025030500183800700_keae274-B2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Beh\u00e7et\u2019s syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"2025030500183800700_keae274-B3","doi-asserted-by":"crossref","first-page":"451675","DOI":"10.1155\/2015\/451675","article-title":"Mucocutaneous involvement in Beh\u00e7et\u2019s disease: how systemic treatment has changed in the last decades and future perspectives","volume":"2015","author":"Rotondo","year":"2015","journal-title":"Mediators Inflamm"},{"key":"2025030500183800700_keae274-B4","doi-asserted-by":"crossref","first-page":"e229527","DOI":"10.1136\/bcr-2019-229527","article-title":"Beh\u00e7et\u2019s disease presenting as recurrent oral aphthosis in a 9-year-old boy from Greece","volume":"13","author":"Panos","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025030500183800700_keae274-B5","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.3889\/oamjms.2019.689","article-title":"Oral ulcers presentation in systemic diseases: an update","volume":"7","author":"Minhas","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"2025030500183800700_keae274-B6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-015-0341-7","article-title":"Genital ulcer severity score and genital health quality of life in Beh\u00e7et\u2019s disease","volume":"10","author":"Senusi","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"2025030500183800700_keae274-B7","first-page":"2953676","article-title":"Genital ulcer of Beh\u00e7et disease localized in the vagina may lack pain, making it difficult to assess","volume":"2019","author":"Obata","year":"2019","journal-title":"Case Rep Rheumatol"},{"key":"2025030500183800700_keae274-B8","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025030500183800700_keae274-B9","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s11739-023-03410-9","article-title":"Unfolding dermatologic spectrum of Beh\u00e7et\u2019s disease in Italy: real-life data from the International AIDA Network Beh\u00e7et\u2019s disease Registry","volume":"18","author":"D\u2019Onghia","year":"2023","journal-title":"Intern Emerg Med"},{"key":"2025030500183800700_keae274-B10","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3899\/jrheum.161352","article-title":"Developing a core set of outcome measures for Beh\u00e7et disease: report from OMERACT 2016","volume":"44","author":"Hatemi","year":"2017","journal-title":"J Rheumatol"},{"key":"2025030500183800700_keae274-B11","doi-asserted-by":"crossref","first-page":"996571","DOI":"10.3389\/fmed.2022.996571","article-title":"The impact of multifactorial factors on the Quality of Life of Beh\u00e7et\u2019s patients over 10 years","volume":"9","author":"Senusi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025030500183800700_keae274-B12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10067-005-0046-8","article-title":"Quality of life and life satisfaction in patients with Beh\u00e7et\u2019s disease: relationship with disease activity","volume":"25","author":"Bodur","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2025030500183800700_keae274-B13","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13075-020-02362-1","article-title":"Discordance between patient and physician global assessment of disease activity in Beh\u00e7et\u2019s syndrome: a multicenter study cohort","volume":"22","author":"Floris","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025030500183800700_keae274-B14","first-page":"CD011018","article-title":"Interventions for the management of oral ulcers in Beh\u00e7et\u2019s disease","volume":"2014","author":"Taylor","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025030500183800700_keae274-B15","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et\u2019s syndrome\u2014a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 121","key":"2025030500183800700_keae274-B16","first-page":"43","article-title":"Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Beh\u00e7et\u2019s disease without formation of antidrug antibodies","volume":"37","author":"Verboom","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500183800700_keae274-B17","first-page":"S112","article-title":"Successful treatment of recalcitrant genital ulcers of Beh\u00e7et\u2019s disease with adalimumab after failure of infliximab and etanercept","volume":"27","author":"Olivieri","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500183800700_keae274-B18","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et\u2019s disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500183800700_keae274-B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2025030500183800700_keae274-B20","first-page":"1945","author":"Hatemi"},{"key":"2025030500183800700_keae274-B21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/rheumatology\/kez267","article-title":"Efficacy and safety of apremilast for Beh\u00e7et\u2019s syndrome: a real-life single-centre Italian experience","volume":"59","author":"De Luca","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025030500183800700_keae274-B22","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","article-title":"Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et\u2019s disease","volume":"78","author":"Lopalco","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025030500183800700_keae274-B23","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025030500183800700_keae274-B24","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1097\/RHU.0000000000001005","article-title":"Healing of mucocutaneous lesions with apremilast in Beh\u00e7et disease","volume":"26","author":"Moya","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"2025030500183800700_keae274-B25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1358\/dot.2020.56.5.3147942","article-title":"Apremilast to treat oral ulcers in Beh\u00e7et syndrome","volume":"56","author":"Yazici","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"2025030500183800700_keae274-B26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et\u2019s Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025030500183800700_keae274-B27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025030500183800700_keae274-B28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et\u2019s disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"2025030500183800700_keae274-B29","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3390\/ijms21093072","article-title":"Beh\u04abet\u2019s disease, and the role of TNF-\u03b1 and TNF-\u03b1 blockers","volume":"21","author":"van der Houwen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"Suppl 132","key":"2025030500183800700_keae274-B30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"39","author":"Hatemi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 127","key":"2025030500183800700_keae274-B31","first-page":"69","article-title":"Apremilast in refractory orogenital ulcers and other manifestations of Beh\u00e7et\u2019s disease. A national multicentre study of 51 cases in clinical practice","volume":"38","author":"Atienza-Mateo","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025030500183800700_keae274-B32","doi-asserted-by":"crossref","first-page":"626792","DOI":"10.3389\/fimmu.2020.626792","article-title":"Apremilast in refractory Beh\u00e7et\u2019s syndrome: a multicenter observational study","volume":"11","author":"Vieira","year":"2020","journal-title":"Front Immunol"},{"key":"2025030500183800700_keae274-B33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jop.13020","article-title":"Value of colchicine as treatment for recurrent oral ulcers: a systematic review","volume":"49","author":"Cabras","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"2025030500183800700_keae274-B34","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2025030500183800700_keae274-B35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1756-185X.12732","article-title":"Safety profile of biologic agents for Beh\u00e7et\u2019s disease in a multicenter observational cohort study","volume":"20","author":"Cantarini","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2025030500183800700_keae274-B36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025030500183800700_keae274-B37","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et\u2019s disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"2025030500183800700_keae274-B38","first-page":"e217","article-title":"Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases\u2014a systematic review","volume":"24","author":"Strietzel","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2025030500183800700_keae274-B39","doi-asserted-by":"crossref","first-page":"e001192","DOI":"10.1136\/rmdopen-2020-001192","article-title":"Development and preliminary validation of the Beh\u00e7et\u2019s syndrome Overall Damage Index (BODI)","volume":"6","author":"Piga","year":"2020","journal-title":"RMD Open"},{"key":"2025030500183800700_keae274-B40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/14397595.2020.1830504","article-title":"Efficacy and safety of apremilast for 3 months in Beh\u00e7et\u2019s disease: a prospective observational study","volume":"31","author":"Hirahara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025030500183800700_keae274-B41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et\u2019s disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025030500183800700_keae274-B42","first-page":"616","article-title":"De novo tuberculosis during infliximab therapy in a patient with Beh\u00e7et disease","volume":"7","author":"Skvara","year":"2009","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae274\/58177584\/keae274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1302\/58177584\/keae274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/3\/1302\/58177584\/keae274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:21:30Z","timestamp":1741134090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/3\/1302\/7685403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae274","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,5,30]]}}}